Research Analysts Set Expectations for XENE FY2029 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Wedbush issued their FY2029 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico expects that the biopharmaceutical company will post earnings of $5.54 per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share.

A number of other analysts have also weighed in on XENE. Raymond James reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $56.00.

Xenon Pharmaceuticals Trading Down 0.1 %

Xenon Pharmaceuticals stock opened at $39.95 on Friday. Xenon Pharmaceuticals has a twelve month low of $35.53 and a twelve month high of $50.99. The stock’s fifty day simple moving average is $40.20 and its 200-day simple moving average is $40.80. The firm has a market capitalization of $3.05 billion, a P/E ratio of -14.17 and a beta of 1.20.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same period in the previous year, the business posted ($0.73) earnings per share.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the transaction, the director now owns 23,573 shares in the company, valued at $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Insiders own 5.52% of the company’s stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in Xenon Pharmaceuticals by 2.2% in the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after acquiring an additional 149,511 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 2.3% during the second quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock worth $172,315,000 after buying an additional 97,732 shares during the period. Wellington Management Group LLP boosted its stake in shares of Xenon Pharmaceuticals by 0.4% during the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock worth $151,317,000 after buying an additional 15,226 shares during the period. Braidwell LP boosted its stake in shares of Xenon Pharmaceuticals by 5.7% during the third quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company’s stock worth $106,585,000 after buying an additional 146,682 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of Xenon Pharmaceuticals by 144.2% during the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after buying an additional 1,507,135 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.